Demis Hassabis, CEO of Google DeepMind, indicated that clinical trials for AI-designed drugs may begin this year, revolutionizing medicine. His spin-off, Isomorphic Labs, aims to accelerate drug development using machine learning since 2021. Hassabis envisions a future with personalized medicine optimized by AI, minimizing time and costs significantly. Although the high cost and lengthy process of traditional drug approval presents challenges, Hassabis believes that advancements in generating quality training data could mitigate these issues, indicating a promising path forward in pharmaceutical innovation.
Eventually you could imagine personalized medicine where it's optimized, maybe overnight, by an AI system for your personal metabolism.
AI has the potential to save pharmaceutical companies lots of time and money, revolutionizing the drug discovery process.
Collection
[
|
...
]